Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised a €7.5 million ($7.9 million) series A round in October, the company is gearing up to file an IND in January on its first compound, EYS606, a TNFα-quenching gene therapy for non-infectious uveitis.
However, while the biotech believes its technology will offer better safety and efficacy than injectables, it faces steep competition from a burst of new technologies also aiming for better PK profiles and less invasive delivery than the ophthalmic therapies that have entered the market in the last 10 years.
Eyevensys developed its delivery system to avoid the concentration peaks and valleys produced by injectable proteins used in vascular eye diseases that lead to toxicity and waning efficacy, respectively.
CEO Raffy Kazandjian told BioCentury the electroporation-based method is minimally invasive and designed to work with a single dose